# Xilio Therapeutics, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:f36f5d74-9de5-451e-bb80-31d7211a5e70 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/xilio-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 27 | | Claims under review | 1 | | Evidence records | 5 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-16T13:53:16.622146+00:00 | | Last reviewed | 2026-10-16T13:53:16.622146+00:00 | ## Identity - Legal name: Xilio Therapeutics, Inc. - Display name: Xilio Therapeutics, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-17T01:43:08.721501+00:00 | | Completeness | 0.409 | | Record Quality | 0.832 | | Directors | 17 | | Committees | 1 | | Governance events | 10 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Akintunde Bello: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2025-01-01. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:6 - Aoife Brennan: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2024-01-01. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:8 - Cheryl Blanchard: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2026-01-01. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:10 - Daniel Curran: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:12 - James Shannon: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2024-01-01. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:14 - René Russo: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2026-04-28. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:16 - Robert Ross: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2022-01-01. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:18 - Yuan Xu: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2022-01-01. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:20 - Akintunde Bello, Ph.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:7 - Aoife Brennan, M.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:9 - Cheryl Blanchard, Ph.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:11 - Daniel Curran, M.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:13 - James Shannon, M.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:15 - René Russo, Pharm.D.: President, Chief Executive Officer and Director. Status: unknown. Independent: false. Since: NOT_PUBLISHED. Committees: Chief Executive Officer and Director (member). claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:17 - Robert Ross, M.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:19 - Sara M. Bonstein: Chair of the Board. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:5 - Yuan Xu, Ph.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:21 ## Committees - Chief Executive Officer and Director (executive). Chair: NOT_PUBLISHED. Members: René Russo, Pharm.D. (member, unknown). committee_id=alpha:committee:xilio-therapeutics-inc:chief-executive-officer-and-director ## Executive leadership - Katarina Luptakova: Named Executive Officer. Status: current. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:23 - Ren Russo: Named Executive Officer. Status: current. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:26 - Christopher Frankenfield: Chief Financial and Operating Officer. Status: unknown. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:22 - Katarina Luptakova, M.D.: Chief Medical Officer. Status: unknown. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:24 - Kevin Brennan: Senior Vice President, Finance and Accounting. Status: unknown. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:25 - René Russo, Pharm.D.: President and Chief Executive Officer [CEO]. Status: unknown. claim_id=alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:27 ## Governance events - DIRECTOR_APPOINTED: René Russo seat on Xilio Therapeutics, Inc., effective 2026-04-28. Effective: 2026-04-28. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:wlnm8wa3cc9i - EXECUTIVE_APPOINTED: Katarina Luptakova executive of Xilio Therapeutics, Inc., effective 2026-04-28. Effective: 2026-04-28. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:g34bfylzmbeu - EXECUTIVE_APPOINTED: Ren Russo executive of Xilio Therapeutics, Inc., effective 2026-04-28. Effective: 2026-04-28. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:1y39fcf15ds5az - DIRECTOR_APPOINTED: Cheryl Blanchard seat on Xilio Therapeutics, Inc., effective 2026-01-01. Effective: 2026-01-01. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:12r93ngsjj9l2 - DIRECTOR_APPOINTED: Akintunde Bello seat on Xilio Therapeutics, Inc., effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:1tf16u4llnoqq - DIRECTOR_APPOINTED: Aoife Brennan seat on Xilio Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:p0mthn5imfdp - DIRECTOR_APPOINTED: James Shannon seat on Xilio Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:rwd0zg1sg0m6s - DIRECTOR_APPOINTED: Robert Ross seat on Xilio Therapeutics, Inc., effective 2022-01-01. Effective: 2022-01-01. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:xom1521kq7q92 - DIRECTOR_APPOINTED: Yuan Xu seat on Xilio Therapeutics, Inc., effective 2022-01-01. Effective: 2022-01-01. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:1n2y20n11cywzt - DIRECTOR_APPOINTED: Daniel Curran seat on Xilio Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-16T13:53:16.622146+00:00. event_id=alpha:event:transition:63ives12p3c1e ## Scoped resources - `alpha://company/xilio-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record - `alpha://company/xilio-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=identity - `alpha://company/xilio-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/xilio-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=board - `alpha://company/xilio-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=committees - `alpha://company/xilio-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=leadership - `alpha://company/xilio-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=ownership - `alpha://company/xilio-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=financials - `alpha://company/xilio-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/xilio-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=compensation - `alpha://company/xilio-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=governance - `alpha://company/xilio-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/xilio-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=audit - `alpha://company/xilio-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=legal - `alpha://company/xilio-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=risk - `alpha://company/xilio-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=cyber - `alpha://company/xilio-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/xilio-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=agents - `alpha://company/xilio-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/xilio-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=events - `alpha://company/xilio-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=relationships - `alpha://company/xilio-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=assessments - `alpha://company/xilio-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - NO_RECORDS_FOUND ## Leadership - Sara M. Bonstein: Chair of the Board. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:5. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Akintunde Bello: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:6. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - Akintunde Bello, Ph.D.: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:7. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Aoife Brennan: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:8. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - Aoife Brennan, M.D.: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:9. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Cheryl Blanchard: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:10. Valid from: 2026-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - Cheryl Blanchard, Ph.D.: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:11. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Daniel Curran: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:12. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - Daniel Curran, M.D.: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:13. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - James Shannon: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:14. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - James Shannon, M.D.: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:15. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - René Russo: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:16. Valid from: 2026-04-28. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - René Russo, Pharm.D.: President, Chief Executive Officer and Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Robert Ross: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:18. Valid from: 2022-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - Robert Ross, M.D.: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Yuan Xu: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:20. Valid from: 2022-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254. - Yuan Xu, Ph.D.: Director. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Christopher Frankenfield: Chief Financial and Operating Officer. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:22. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Katarina Luptakova: Named Executive Officer. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:23. Valid from: 2026-04-28. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:35adda5dbc4f0f752d35d0ed85c09faf4e6000a77023d119f62211396a9b0495. - Katarina Luptakova, M.D.: Chief Medical Officer. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:24. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Kevin Brennan: Senior Vice President, Finance and Accounting. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:25. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. - Ren Russo: Named Executive Officer. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:26. Valid from: 2026-04-28. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:151da3cc930c16fde8e744aee581684546ce1b2c6c4d19a262712da1458826ea. - René Russo, Pharm.D.: President and Chief Executive Officer. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:leadership_role:27. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - PUBLISHED ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Xilio Therapeutics, Inc.. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:992daee6ee64ae2038b4ede96283a9a2bf3cc7b9eeb6bbdf17212792847082c9. ## Entity Status - Public listing published. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:992daee6ee64ae2038b4ede96283a9a2bf3cc7b9eeb6bbdf17212792847082c9. ## Published Fact - US. Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:992daee6ee64ae2038b4ede96283a9a2bf3cc7b9eeb6bbdf17212792847082c9. ## Security Listing - XLO (NASDAQ). Claim: alpha:claim:company:f36f5d74-9de5-451e-bb80-31d7211a5e70:security_listing:28. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:992daee6ee64ae2038b4ede96283a9a2bf3cc7b9eeb6bbdf17212792847082c9. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:992daee6ee64ae2038b4ede96283a9a2bf3cc7b9eeb6bbdf17212792847082c9: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/xilio-therapeutics-inc). - alpha:projection-evidence:document:63816c7eb4e9bdbc461c40730c2ea8fc2dfe84862abb6369ef7c769ad55881ea: [SEC DEF 14A 0001193125-26-187642](https://www.sec.gov/Archives/edgar/data/1840233/000119312526187642/xlo-20260428.htm). - alpha:projection-evidence:document:cefce36e56ecb150672e2aff86279e4cc974da525237fbc531b638bad90af254: [DEF 14A xlo-20260428.htm](https://www.sec.gov/Archives/edgar/data/1840233/000119312526187642/xlo-20260428.htm). - alpha:projection-evidence:document:35adda5dbc4f0f752d35d0ed85c09faf4e6000a77023d119f62211396a9b0495: [XLO DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1840233/000119312526187642/xlo-20260428.htm). - alpha:projection-evidence:document:151da3cc930c16fde8e744aee581684546ce1b2c6c4d19a262712da1458826ea: [XLO DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1840233/000119312526187642/xlo-20260428.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/xilio-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/xilio-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/xilio-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/xilio-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-17T01:43:08.53027+00:00; recorded 2026-10-17T01:43:08.53027+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.